Appointment of Chief Financial Officer and Board Changes

Summary by AI BETAClose X

4basebio PLC has appointed Richard Bungay as Chief Financial Officer, effective July 2026, bringing extensive experience in fundraising, M&A, and strategic finance within the biotech sector, including a $670 million Series A raise and a $1.5 billion acquisition. This appointment coincides with board changes, including the departure of Alexander Link and Alan Malus, with Dr. Heikki Lanckriet taking over Mr. Link's role and Cornel Chiriac expected to replace Mr. Malus pending approvals. The company anticipates Bungay's expertise will be crucial as it enters a phase of accelerated commercial growth for its synthetic DNA manufacturing services.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings